Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer ...
Jan 5, 2015
0
10
Cancer Research UK's Centre for Drug Development (CDD), in collaboration with the Rising Tide Foundation (link is external), a Swiss-based non-profit organisation which funds innovative cancer trials, today (TUESDAY) announce ...
Sep 30, 2014
0
0
Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form ...
Sep 25, 2014
0
1
(Medical Xpress)—Researchers have discovered how one segment of an important regulatory protein changes shape so it can fulfill multiple roles in the life of cells, including tumor suppression. St. Jude Children's Research ...
Jul 3, 2014
0
0
Drug developers are facing the perfect storm. They are confronted with major patent expiries, increased payer scrutiny, changing priorities, shifting business models, increased risk averseness, increased clinical trial costs, ...
Jul 1, 2014
0
0
A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells. Their ...
May 21, 2014
0
0
(Medical Xpress)—Their work has identified a protein called PIP4K2A that could be a new target in drug development.
May 16, 2014
0
0
(Medical Xpress)—The first human trial of a pioneering personalised cancer treatment developed at Oxford University will begin this week, with the potential to tackle a wide range of late-stage cancers.
Mar 14, 2014
0
0
A new study in Cell Reports identifies a gene important to breast development and breast cancer, providing a potential new target for drug therapies to treat aggressive types of breast cancer.
Mar 6, 2014
0
0
Cancer Research UK's Drug Development Office (DDO) has launched a new clinical trial to treat lymphoma patients using the body's own immune system to attack cancerous B-cells growing out of control.
Jan 29, 2014
0
0
